Ethyl 4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzoate

We are Ethyl 4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzoate CAS:641569-97-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:Ethyl 4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzoate
CAS.NO:641569-97-3
Synonyms:4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoicacid ethyl ester
Molecular Formula:C19H18N4O2
Molecular Weight:334.37200
 
Physical and Chemical Properties:
Density:1.233
Boiling point:546.1ºC
 
Specification:
Appearance:Off-white powder
Purity:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Nilotinib
 
Note:The product under valid patents will not be offered to the countries covered by patents.

Ethyl 4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzoate


Related News: Pharmaceutical intermediates: chemical raw materials or chemical products used in the process of pharmaceutical synthesis, are intermediate products in the process of producing APIs, and can be further processed into APIs.1- (Clorometil) -2- (trifluorometoxi) benceno CAS:116827-40-8 The policy-oriented emphasis on the medical and pharmaceutical industries and the direct support for the chemical raw material pharmaceutical industry have created a good political environment for the development of related enterprises and laid the foundation for the rapid development of the chemical raw material pharmaceutical industry. The good development prospects of the chemical raw material pharmaceutical industry will be passed directly to the upstream raw material industry, which will help stimulate the demand for the pharmaceutical intermediate market.Dichloromethylvinylsilane CAS:124-70-9 The on-body wear is similar to that of an insulin pump. Unlike insulin pump therapy, however, the investigational system is designed such that users enter only their body weight for the iLet to initialize therapy.17745-04-9 In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.

Related Products
Product Name
2-(2-methyl-2H-tetrazol-5-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine View Details
phloroglucinol View Details
8-Bromo-1-octanol View Details
2-fluoro-5-[(Z)-(3-oxo-2-benzofuran-1-ylidene)methyl]benzonitrile manufacturer 2,5-Dimethoxyphenylboronic acid manufacturer N-Boc-glycine Ethyl Ester manufacturer 2-Bromo-3-fluorobenzoic acid manufacturer Ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate manufacturer